Cargando…
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)
Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain...
Autores principales: | Schimanski, Carl Christoph, Kasper, Stefan, Hegewisch-Becker, Susanna, Schröder, Jan, Overkamp, Friedrich, Kullmann, Frank, Bechstein, Wolf Otto, Vöhringer, Matthias, Öllinger, Robert, Lordick, Florian, Heinemann, Volker, Geißler, Michael, Schulz-Abelius, Armin, Bernhard, Helga, Schön, Michael R., Greil, Richard, Galle, Peter, Lang, Hauke, Schmidtmann, Irene, Moehler, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458621/ https://www.ncbi.nlm.nih.gov/pubmed/32923171 http://dx.doi.org/10.1080/2162402X.2020.1806680 |
Ejemplares similares
-
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
por: Schimanski, Carl Christoph, et al.
Publicado: (2012) -
Cyclophosphamide mechanism of action in preclinical tecemotide studies
por: Hance, Ken, et al.
Publicado: (2013) -
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
por: Moehler, Markus, et al.
Publicado: (2016) -
Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy
por: Kao, Chiao-Jung, et al.
Publicado: (2013) -
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
por: Hoehler, T, et al.
Publicado: (2013)